Milpitas (CA USA), Nov 16th, 2015 – Applied StemCell, Inc. (ASC) and iPS Academia Japan, Inc. (Kyoto, Japan) announced today both parties have entered into a non-exclusive agreement granting ASC access to a patent portfolio relating to the generation of induced Pluripotent Stem cell (iPSC) , enabling ASC to expand its business in the area of iPSC generation, differentiation and gene modification. This agreement enables ASC to accelerate its technology development for disease modeling, drug discovery, and its unique iPSC expansion/differentiation methods in basic research. With its global distribution network and IP technologies, ASC is focusing on developing new services with the aim of growing its contract research businesses in the regenerative/personalized medicine fields.
The patents related to iPSC technologies are from the work of Professor Shinya Yamanaka, a winner of the 2012 Nobel Prize, of the Center for iPS Cell Research and Application (CiRA) at the Kyoto University Japan. This technology has a great potential in that scientists can generate iPSCs from patient-derived samples which can be further differentiated into different cell types and widely used in basic research/pre-clinical applications.
About Applied StemCell, Inc.
Applied StemCell, Inc. is a fast-growing biotechnology company providing laboratory animal and cell line models as tools for pre-clinical research, drug discovery and diagnostics. Using its proprietary TARGATT™ genome modification technology, ASC can efficiently generate site-specific knock-in mouse, rat and human cell line models for the bio-pharmaceutical and academic research communities. For more information please visit:www.appliedstemcell.com.
About iPS Academia Japan, Inc.
iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other institutions in the field of iPS cell technologies so that the research results contribute to health and welfare worldwide. AJ was established in Kyoto in June 2008. AJ’s patent portfolio consists of approx. 120 patent families (approx. 390 patent application cases, of which approx. 140 issued) in iPS cell technologies as of September 2015, and more than 150 license arrangements have been executed with domestic or international entities. For more information, visit www.ips-cell.net.
Licensing agreement with iPS Academia, Japan. is a post from: Blog - Applied StemCell
The post Licensing agreement with iPS Academia, Japan. appeared first on Blog - Applied StemCell.
